26
|
Satomi E, Ishiki H, Yokota T, Tada Y, Sato H, Okamoto M, Osaka I. Efficacy and tolerability of naldemedine in patient with cancer and opioid-induced constipation: A pooled subgroup analysis of 2 randomized placebo-controlled studies. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy300.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Ikeda S, Yokota T, Fukui K, Hoshino T. P3.01-41 Anatomical and Clinical Basis of #11 LN by Systematic Bilateral Mediastinal Nodal Dissection for Left Lung Cancer through Median Sternotomy. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
28
|
Fukui K, Ikeda S, Yokota T, Hoshino T. P3.CR-01 To Better Understand the Anatomical Proximity of Cardiac Plexus to Prevent Lethal Arrhythmias Associated with Lung Cancer Surgery. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
29
|
Nomura M, Andoh M, Yokota T, Miyazaki T, Satake H, Iwasawa S, Sonoda A, Kato K, Muto M. Phase II trial on nivolumab in patients with unresectable or metastatic mucosal melanoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Yokota T, Ikeda S. P2.17-31 The Effect of the Extended Bilateral Mediastinal Lymph Node Dissection Through a Median Sternotomy for Non-Small-Cell Carcinoma of the Left Lung. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Omote K, Nagai T, Asakawa N, Komoriyama H, Kato Y, Aikawa T, Tokuda Y, Kamiya K, Nishida M, Kudo Y, Fukushima A, Iwano H, Yokota T, Anzai T. P2812Long-term prognostic significance of liver stiffness non-invasively measured by the virtual touch quantification in patients with acute decompensated heart failure. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Kakutani N, Fukushima A, Yokota T, Katayama T, Nambu H, Shirakawa R, Maekawa S, Abe T, Takada S, Furihata T, Okita K, Kinugawa S, Anzai T. P6057High respiratory exchange ratio during submaximal exercise predicts adverse clinical outcomes in patients with heart failure. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Nambu H, Takada S, Fukushima A, Matsumoto J, Kakutani N, Maekawa S, Shirakawa R, Furihata T, Nakajima T, Katayama T, Tsuda M, Saito A, Yokota T, Kinugawa S, Anzai T. P4774Empagliflozin improves exercise endurance via the activation of fatty acid oxidation in the skeletal muscle in murine model of post-infarct heart failure. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Omote K, Nagai T, Asakawa N, Aikawa T, Tokuda Y, Kato Y, Kamiya K, Komoriyama H, Nishida M, Kudo Y, Fukushima A, Iwano H, Yokota T, Anzai T. P3734Clinical value of a non-invasive measurement of increased liver stiffness by using virtual touch quantification for predicting elevated right atrial pressure in heart failure patients. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Shirakawa R, Yokota T, Nakajima T, Takada S, Yamane M, Furihata T, Matsumoto J, Tsuda M, Katayama T, Maekawa S, Nambu H, Fukushima A, Saito A, Kinugawa S, Anzai T. 3143Excessive mitochondrial reactive oxygen species emission from circulating blood cells is associated with severity of heart failure and exercise intolerance. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.3143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, Arai M, Tada Y, Narabayashi M, Boku N. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Ann Oncol 2018; 29:1461-1467. [PMID: 32151367 PMCID: PMC6005145 DOI: 10.1093/annonc/mdy118] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND The efficacy and safety of naldemedine (a peripherally acting µ-opioid receptor antagonist) for opioid-induced constipation (OIC) in subjects with cancer was demonstrated in the primary report of a phase III, double-blind study (COMPOSE-4) and its open-label extension (COMPOSE-5). The primary end point, the proportion of spontaneous bowel movement (SBM) responders, was met. Here, we report results from secondary end points, including quality of life (QOL) assessments from these studies. PATIENTS AND METHODS In COMPOSE-4, eligible adults with OIC and cancer were randomly assigned 1:1 to receive once-daily oral naldemedine 0.2 mg (n = 97) or placebo (n = 96) for 2 weeks, and those who continued on to COMPOSE-5 received naldemedine for 12 weeks (n = 131). Secondary assessments in COMPOSE-4 included the proportion of complete SBM (CSBM) responders, SBM or CSBM responders by week, and subjects with ≥1 SBM or CSBM within 24 h postinitial dose. Changes from baseline in the frequency of SBMs or CSBMs per week were assessed at weeks 1 and 2. Time to the first SBM or CSBM postinitial dose was also evaluated. In both studies, QOL impact was evaluated by Patient Assessment of Constipation-Symptoms (PAC-SYM) and PAC-QOL questionnaires. RESULTS Naldemedine improved bowel function for all secondary efficacy assessments versus placebo (all P ≤ 0.0002). The timely onset of naldemedine activity versus placebo was evidenced by median time to the first SBM (4.7 h versus 26.6 h) and CSBM (24.0 h versus 218.5 h) postinitial dose (all P < 0.0001). In COMPOSE-4, significant differences between groups were observed with the PAC-SYM stool domain (P = 0.045) and PAC-QOL dissatisfaction domain (P = 0.015). In COMPOSE-5, significant improvements from baseline were observed for overall and individual domain scores of PAC-SYM and PAC-QOL. CONCLUSIONS Naldemedine provided effective and timely symptomatic relief from OIC and improved the QOL of subjects with OIC and cancer. TRIAL REGISTRATION ID: www.ClinicalTrials.jp: JAPIC-CTI-132340 (COMPOSE-4) and JAPIC-CTI-132342 (COMPOSE-5).
Collapse
|
37
|
Tahara M, Kiyota N, Yokota T, Hasegawa Y, Muro K, Takahashi S, Onoe T, Homma A, Taguchi J, Suzuki M, Minato K, Yane K, Ueda S, Hara H, Saijo K, Yamanaka T. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Ann Oncol 2018; 29:1004-1009. [DOI: 10.1093/annonc/mdy040] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
|
38
|
van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, Sabet A, George K, Roberts L, Carne R, Blum S, Henderson R, Van Damme P, Demeestere J, Larue S, D'Amour C, Bril V, Breiner A, Kunc P, Valis M, Sussova J, Kalous T, Talab R, Bednar M, Toomsoo T, Rubanovits I, Gross-Paju K, Sorro U, Saarela M, Auranen M, Pouget J, Attarian S, Le Masson G, Wielanek-Bachelet A, Desnuelle C, Delmont E, Clavelou P, Aufauvre D, Schmidt J, Zschuentssch J, Sommer C, Kramer D, Hoffmann O, Goerlitz C, Haas J, Chatzopoulos M, Yoon R, Gold R, Berlit P, Jaspert-Grehl A, Liebetanz D, Kutschenko A, Stangel M, Trebst C, Baum P, Bergh F, Klehmet J, Meisel A, Klostermann F, Oechtering J, Lehmann H, Schroeter M, Hagenacker T, Mueller D, Sperfeld A, Bethke F, Drory V, Algom A, Yarnitsky D, Murinson B, Di Muzio A, Ciccocioppo F, Sorbi S, Mata S, Schenone A, Grandis M, Lauria G, Cazzato D, Antonini G, Morino S, Cocito D, Zibetti M, Yokota T, Ohkubo T, Kanda T, Kawai M, Kaida K, Onoue H, Kuwabara S, Mori M, Iijima M, Ohyama K, Baba M, Tomiyama M, Nishiyama K, Akutsu T, Yokoyama K, Kanai K, van Schaik I, Eftimov F, Notermans N, Visser N, Faber C, Hoeijmakers J, Rejdak K, Chyrchel-Paszkiewicz U, Casanovas Pons C, Alberti Aguiló M, Gamez J, Figueras M, Marquez Infante C, Benitez Rivero S, Lunn M, Morrow J, Gosal D, Lavin T, Melamed I, Testori A, Ajroud-Driss S, Menichella D, Simpson E, Chi-Ho Lai E, Dimachkie M, Barohn R, Beydoun S, Johl H, Lange D, Shtilbans A, Muley S, Ladha S, Freimer M, Kissel J, Latov N, Chin R, Ubogu E, Mumfrey S, Rao T, MacDonald P, Sharma K, Gonzalez G, Allen J, Walk D, Hobson-Webb L, Gable K. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2018; 17:35-46. [DOI: 10.1016/s1474-4422(17)30378-2] [Citation(s) in RCA: 130] [Impact Index Per Article: 21.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2017] [Revised: 09/28/2017] [Accepted: 10/02/2017] [Indexed: 10/18/2022]
|
39
|
Yokota T, Ikeda S. PUB053 Surgery for Non-Small-Cell Lung Cancer with Malignant Minor Pleural Effusion Detected on Thoracotomy. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
40
|
Anraku Y, Kuwahara H, Fukusato Y, Mizoguchi A, Ishii T, Nitta K, Matsumoto Y, Toh K, Miyata K, Uchida S, Nishina K, Osada K, Itaka K, Nishiyama N, Mizusawa H, Yamasoba T, Yokota T, Kataoka K. Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain. Nat Commun 2017; 8:1001. [PMID: 29042554 PMCID: PMC5645389 DOI: 10.1038/s41467-017-00952-3] [Citation(s) in RCA: 151] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Accepted: 08/07/2017] [Indexed: 01/11/2023] Open
Abstract
Recently, nanocarriers that transport bioactive substances to a target site in the body have attracted considerable attention and undergone rapid progression in terms of the state of the art. However, few nanocarriers can enter the brain via a systemic route through the blood-brain barrier (BBB) to efficiently reach neurons. Here we prepare a self-assembled supramolecular nanocarrier with a surface featuring properly configured glucose. The BBB crossing and brain accumulation of this nanocarrier are boosted by the rapid glycaemic increase after fasting and by the putative phenomenon of the highly expressed glucose transporter-1 (GLUT1) in brain capillary endothelial cells migrating from the luminal to the abluminal plasma membrane. The precisely controlled glucose density on the surface of the nanocarrier enables the regulation of its distribution within the brain, and thus is successfully optimized to increase the number of nanocarriers accumulating in neurons.There are only a few examples of nanocarriers that can transport bioactive substances across the blood-brain barrier. Here the authors show that by rapid glycaemic increase the accumulation of a glucosylated nanocarrier in the brain can be controlled.
Collapse
|
41
|
Yokote H, Kamata T, Toru S, Sanjo N, Yokota T. Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
van Westering T, Johansson H, Coenen-Stass A, Miyatake S, Tanihata J, Takeda S, Yokota T, Lehtiö J, Wood M, El Andaloussi S, Roberts T, Aoki Y. Comparative high resolution proteomic analysis of dystrophic mouse models reveals a core dystrophic proteome and the impact of aging. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Ozaki K, Doi H, Mitsui J, Sato N, Yamane K, Majima T, Irioka T, Ishiura H, Doi K, Morishita S, Koyama K, Miura Y, Matsumoto N, Tanaka F, Tsuji S, Mizusawa H, Yokota T, Ishikawa K. Clinicoradiological characteristics of SCA34 patients with the hot cross bun sign caused by the P.TRP246GLY mutation in ELOVL4. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
44
|
Numasawa Y, Hattori T, Ishiai S, Kobayashi Z, Kamata T, Kotera M, Ishibashi S, Sanjo N, Mizusawa H, Yokota T. Components of depressive disorder due to raphe-nuclei damage: Subclass analysis of patients with brainstem infarction. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.1794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Yoshioka K, Kunieda T, Asami Y, Sujino Y, Tanaka K, Piao W, Kuwahara H, Nishina K, Nagata T, Yokota T. Dual overhanging-duplex oligonucleotide improved efficacy and safety in gene therapy for FAP. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
46
|
Iwasawa E, Li F, Ishibashi S, Ichijo M, Miki K, Yokota T. Expression of sphingosine-1-phosphate receptor 1 in leptomeningeal arteries is upregulated and its agonist improves neurological outcome in ischemic stroek in mice. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
Ichinose K, Ishibashi S, Miyashita A, Sanjo N, Uchida K, Suzuki Y, Sekine M, Kobayashi D, Eishi Y, Yokota T. Clinicopathological features of neuromuscular sarcoidosis and its immunoreactivity profiles of P. acne. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
48
|
Uehara T, Choong C, Hayakawa H, Kasahara Y, Nagata T, Yokota T, Baba K, Nakamori M, Obika S, Mochizuki H. Antisense oligonucleotides containing amido-bridged nucleic acid reduce SNCA expression and improve motor function in Parkinson's disease animal models. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2950] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
49
|
Matsushita T, Nakamura Y, Niino M, Fukaura H, Tanaka M, Ochi H, Kanda T, Yokota T, Matsui M, Kusunoki S, Terayama Y, Kawachi I, Ohashi T, Shimohama S, Nishiyama K, Nakatsuji Y, Suzumura A, Ochi K, Yamamoto K, Yamasaki R, Kawano Y, Tsuji S, Hinomura A, Tada M, Matsuyama A, Shimizu Y, Nagaishi A, Okada K, Shinoda K, Isobe N, Kira J. Clinical and genetic features of Japanese patients with multiple sclerosis and neuromyelitis optica spectrum disorder based on Japan multiple sclerosis biobank. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
50
|
Yagi Y, Yokota T. Next-generation sequencing-based small RNA profiling of cerebrospinal fluid exosomes. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2733] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|